Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (GREY:VBIVQ)

VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Business Wire March 15, 2022

VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022

Business Wire March 7, 2022

QualTek Names New Independent Board Appointees to its Board of Directors

PR Newswire March 7, 2022

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

Business Wire February 25, 2022

VBI Vaccines Announces PreHevbrio(TM) [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

Business Wire February 23, 2022

VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference

Business Wire January 26, 2022

VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio

Business Wire January 5, 2022

VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada

Business Wire December 9, 2021

VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021

Business Wire December 1, 2021

VBI Vaccines Announces FDA Approval of PreHevbrio(TM) for the Prevention of Hepatitis B in Adults

Business Wire December 1, 2021

VBI Vaccines to Participate in Jefferies London Healthcare Conference

Business Wire November 16, 2021

VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Business Wire November 8, 2021

VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021

Business Wire November 1, 2021

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open

Business Wire October 13, 2021

VBI Vaccines to Participate in Upcoming Investor Conferences

Business Wire October 4, 2021

VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern

Business Wire September 29, 2021

VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Business Wire August 2, 2021

VBI Vaccines Appoints Linda Bain to Board of Directors

Business Wire July 7, 2021

VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine

Business Wire July 1, 2021

VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19

Business Wire June 29, 2021